Over-the-counter (OTC) short-acting ß2-agonist (SABA) purchase and asthma outcomes in SABINA III
H. Farouk (Dubai, United Arab Emirates), W. Mattarucco (Entre Rios, Argentina), R. Barriga (Chihuahua, Mexico), H. Wang (Taipei, Taiwan), D. Diaz (Manila, Philippines), A. Khattab (Cairo, Egypt), M. Gallego (Pereira, Colombia), A. Zaabi (Abu Dhabi, United Arab Emirates), D. Price (Aberdeen, United Kingdom)
Source: International Congress 2022 – Clinical problems and management of airway diseases
Session: Clinical problems and management of airway diseases
Session type: Thematic Poster
Number: 1652
 
Rating: 
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
H. Farouk (Dubai, United Arab Emirates), W. Mattarucco (Entre Rios, Argentina), R. Barriga (Chihuahua, Mexico), H. Wang (Taipei, Taiwan), D. Diaz (Manila, Philippines), A. Khattab (Cairo, Egypt), M. Gallego (Pereira, Colombia), A. Zaabi (Abu Dhabi, United Arab Emirates), D. Price (Aberdeen, United Kingdom). Over-the-counter (OTC) short-acting ß2-agonist (SABA) purchase and asthma outcomes in SABINA III. 1652
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
|
|